Novo Nordisk EBITDA 2010-2022 | NVO

Novo Nordisk annual and quarterly EBITDA history from 2010 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Novo Nordisk EBITDA for the quarter ending September 30, 2022 was $2.982B, a 13.66% increase year-over-year.
  • Novo Nordisk EBITDA for the twelve months ending September 30, 2022 was $11.390B, a 15.14% increase year-over-year.
  • Novo Nordisk 2021 annual EBITDA was $10.289B, a 12.16% increase from 2020.
  • Novo Nordisk 2020 annual EBITDA was $9.173B, a 5.25% increase from 2019.
  • Novo Nordisk 2019 annual EBITDA was $8.716B, a 11.39% increase from 2018.
Novo Nordisk Annual EBITDA
(Millions of US $)
2021 $10,289
2020 $9,173
2019 $8,716
2018 $7,824
2017 $7,921
2016 $7,671
2015 $7,798
2014 $6,762
2013 $6,107
2012 $5,558
2011 $4,182
2010 $3,808
2009 $3,147
Novo Nordisk Quarterly EBITDA
(Millions of US $)
2022-09-30 $2,982
2022-06-30 $2,851
2022-03-31 $3,136
2021-12-31 $2,421
2021-09-30 $2,623
2021-06-30 $2,593
2021-03-31 $2,652
2020-12-31 $2,024
2020-09-30 $2,366
2020-06-30 $2,215
2020-03-31 $2,568
2019-12-31 $1,963
2019-09-30 $2,234
2019-06-30 $2,191
2019-03-31 $2,328
2018-12-31 $1,616
2018-09-30 $1,959
2018-06-30 $2,073
2018-03-31 $2,176
2017-12-31 $1,744
2017-09-30 $2,030
2017-06-30 $2,111
2017-03-31 $2,036
2016-12-31 $1,778
2016-09-30 $1,971
2016-06-30 $2,010
2016-03-31 $1,913
2015-12-31 $1,771
2015-09-30 $1,882
2015-06-30 $1,944
2015-03-31 $2,201
2014-12-31 $1,544
2014-09-30 $1,525
2014-06-30 $1,605
2014-03-31 $1,476
2013-12-31 $1,346
2013-09-30 $1,419
2013-06-30 $1,504
2013-03-31 $1,339
2012-12-31 $1,323
2012-09-30 $1,322
2012-06-30 $1,322
2012-03-31 $1,126
2011-12-31 $675
2011-09-30 $1,110
2011-06-30 $1,162
2011-03-31 $1,105
2010-12-31 $1,037
2010-09-30 $1,184
2010-06-30 $1,017
2010-03-31 $789
2009-12-31 $1,009
2009-09-30 $806
2009-06-30 $749
2009-03-31 $687
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $287.171B $22.397B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $467.679B 18.00
Eli Lilly (LLY) United States $356.089B 44.94
AbbVie (ABBV) United States $289.429B 12.00
Pfizer (PFE) United States $285.774B 7.81
Merck (MRK) United States $278.995B 14.37
Novartis AG (NVS) Switzerland $199.112B 15.00